After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
68
sitagliptin 100 mg Once a day (QD) for 24 weeks
metformin 850 mg Twice a day (BID) for 24 weeks
metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24
Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.
Time frame: Baseline and 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Patient can take any oral antidiabetic drug (other than metformin)